%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-03-28T09:22:59-05:00
2017-03-28T09:23-05:00
2017-03-28T09:23-05:00
Adobe InDesign CC 2017 (Windows)
uuid:99e8b194-2198-4f7a-996e-08aa0f1640e7
xmp.did:5e04fea8-b29b-c643-9d13-a71790cd99a6
xmp.id:b4fec460-f2aa-8e43-8242-6a7a9968b5ab
proof:pdf
xmp.iid:c57d9dfa-36c2-814f-bd0a-8682cc15b941
xmp.did:4d592983-c0e2-bc4d-a0bc-3a65454a3fae
xmp.did:5e04fea8-b29b-c643-9d13-a71790cd99a6
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-03-28T09:22:59-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
8 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
11 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
34 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0.04 Tc -0.04 Tw 9 0 0 9 529.2283 32.9076 Tm
(37)Tj
0 Tc -0.03 Tw 8 0 0 8 62.3622 675.8339 Tm
[(Secl\351n )17 (Y)160.8 (. La )-0.7 (Carga de Enfermedad )-0.7 (y Lesiones )-0.7 (en )-0.7 (el P)47.2 (er\372. P)47.3 (er\372: )]TJ
0 Tw 0 -1.2 TD
(Ministerio de Salud; 2009.)Tj
-0.032 Tw -1.772 -1.2 Td
(11.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Fano )-1 (VR, )-1.2 (Hern)-0.8 (\341ndez )-1.5 (PM, )-0.9 (Jim\351ne)-1 (z DE, )-0.7 (Longres )-0.8 (MA. )-1.1 (Marcadores )]TJ
-0.006 Tw T*
[(serol\363gicos )0.7 (causan)-1.5 (tes )-1.3 (de )-1.1 (p\351rdidas )-1.5 (de )-0.6 (donaciones. )-1.9 (R)40.5 (ev )-0.8 (Cubana )]TJ
0 Tw T*
(Med Milit.2000;29\(1\):41-5.)Tj
0.508 Tw -1.772 -1.2 Td
(12.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(P)47.3 (an-American )-1.8 (Health )-1.7 (Organizati)-1 (on. Supply of )1 (blood )0.8 (for )]TJ
0.134 Tw T*
[(transfusion )-0.6 (in Latin )53.5 (American )-1 (and )-0.8 (Caribbean )-1.6 (countries )-0.9 (2012 )]TJ
0 Tw T*
[(and 2013. W)52.3 (ashington, DC : P)108.6 (AHO; 2015.)]TJ
0.227 Tw -1.772 -1.2 Td
(13.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ministerio )-1.1 (de )-0.8 (Salud. )-1.2 (Sistema )-1.6 (de )-0.7 (Gesti\363n )-1.4 (de )-0.8 (la )-0.6 (Calidad )-1.5 (del )]TJ
0.211 Tw T*
[(PRONAHEBAS. )0.5 (Man)-1.3 (ual )-0.8 (de )-0.7 (Calidad. )-1.6 (Norma )18 (T\351cnica. )-1.5 (No 011\226)]TJ
0 Tw T*
[(MINSA/ DGSP\226V)144.3 (. 01. 2004.)]TJ
0.118 Tw -1.772 -1.2 Td
(14.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Barbara )-1.1 (JA. Challenges )-2.1 (in )-1 (transfusion )-0.8 (microbiology)122.9 (. )17.4 (T)110.3 (ransfus )]TJ
0 Tw T*
[(Med R)39.2 (ev)134.1 (. 1993;7\(2\):96-103.)]TJ
0.02 Tw -1.772 -1.2 Td
(15.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Schreiber )-1.5 (GB, )-1 (Busch )-1.1 (MP)195.2 (, )-0.8 (Kleinma)-1 (n )-1 (SH, )-1 (K)31.5 (orelitz JJ. )18.1 (The )-0.9 (risk )-0.6 (of )]TJ
0.14 Tw T*
[(transfusion-transmitted )-3.6 (viral infect)-1.2 (ions. N Engl J Med.1996; )]TJ
0 Tw T*
(334:1685-1690)Tj
0.451 Tw -1.772 -1.2 Td
(16.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(P)47.3 (an )54 (American )-1.3 (Health )-2.2 (Organizatio)-0.7 (n. )-0.9 (Supply )-1 (of )0.5 (Blood )0.5 (for )]TJ
0.029 Tw T*
[(T)110.3 (ransfusion )-0.8 (in )-1.2 (the )-1.9 (Caribbean )-2.5 (and )-1.5 (La)-0.8 (tin )53.6 (American )-1.7 (Countries )-1.7 (in )]TJ
0.016 Tw T*
[(2006-2007: )-3.9 (P)47.3 (rogress )0.8 (since )-1.1 (2005 )-1.8 (of )0.5 (the )-1.5 (R)40.5 (egional )-1.1 (Plan of )55.7 (Action )]TJ
0 Tw T*
[(for )18.9 (T)110.3 (ransfusion Safety)120.5 (. W)55.2 (ashington, DC : P)108.5 (AHO; 2009.)]TJ
0.013 Tw -1.772 -1.2 Td
(17.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Sellors J, Zimi)-0.7 (c-V)17.3 (incetic )-2.4 (M, )-1.4 (Howard )-0.8 (M, )-1.3 (Mahony )-2.1 (JB, Chernesky )]TJ
-0.097 Tw T*
[(MA. )-0.9 (P)47.3 (redictors of positivity )-1.3 (for )0.8 (hepatitis )-2.8 (B and )-1.3 (the )-1.6 (derivation )-1.5 (of )]TJ
0.04 Tw T*
[(a )-0.7 (selective )-1.8 (screening )-1.6 (rule )-0.7 (in )-0.9 (a )-0.7 (Canadian )-2.7 (sexually )-1.3 (transmitted )]TJ
0 Tw T*
[(diseases clinic. J Clin V)14.5 (irol. 1998; 11\(1\):85-91.)]TJ
-0.045 Tw -1.772 -1.2 Td
(18.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Blejer JL, Carreras VL, )-0.9 (Salamone )-1.2 (HJ. Riesgo de )17.5 (T)110.3 (ransmisi\363n de )]TJ
-0.049 Tw T*
[(Infecciones )-1.3 (por )0.6 (V\355a)-0.9 ( )18.1 (T)110.3 (ransfusional. )-0.7 (MEDICINA.2002; )-3.1 (62: )-1 (259-278)]TJ
0.195 Tw -1.772 -1.2 Td
(19.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Grifols )1.4 (EJ, )0.7 (Ma)-0.9 (rtin )-1 (VC, )-0.6 (Hern\341nd)-1.6 (ez )0.6 (SJ, Pujol )0.8 (BM, Grifols )1.1 (RJ, )]TJ
0.332 Tw T*
[(Garc\355a )-1.6 (RE. Seguridad )-1.3 (en )-1.4 (Medicina)-2.2 ( )17.5 (T)110.3 (ransfusional. )-1.3 (Menarini )]TJ
0 Tw T*
[(Diagn\363stics. Espa\361a: P)44.5 (ecalo; 1998.)]TJ
0.329 Tw -1.772 -1.2 Td
(20.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Blejer JL, Sartor )0.8 (P)111.7 (A, Botasso )0.5 (O, Salome HJ, Leguizam\363n )]TJ
0.406 Tw T*
[(MS. )17.3 (T)110.3 (rans-sialidase )-1.6 (inhibition )-2.2 (assay )-0.6 (for )1 (the )-1.4 (detection )-2.3 (of )]TJ
0.279 Tw T*
[(T)110.3 (rypanosoma cruzi infection )-1.3 (in blood )0.7 (donor )0.6 (samples from )]TJ
0 Tw T*
[(Argentina. V)61.9 (ox Sang.2008;95\(3\): 189-196. )]TJ
0.234 Tw -1.772 -1.2 Td
(21.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Zur )-0.6 (Hausen )-2.1 (H. )17.4 (The )-0.9 (search )-1.3 (for )0.6 (infectious )-1.5 (causes )-1.4 (of human )]TJ
0 Tw T*
[(cancers: Where and why)117.7 (. V)17.2 (irology)122.9 (.2009;392 \(1\): 1\22610)]TJ
0.098 Tw -1.772 -1.2 Td
(22.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Khabbaz )-1.7 (RF)180.3 (, )-0.8 (Heneine )-2.8 (W)92.2 (, )-0.8 (Grindon )54.2 (A, )-0.7 (Hartley )16.1 (TM, )-0.8 (Shulman )-2.2 (G, )]TJ
0.079 Tw T*
[(Kaplan )-1.4 (J. Indeterminate )-4.2 (HTL)138.4 (V )-0.9 (serologic results )-1 (in )-1 (U.S. )-1.3 (blood )]TJ
0.131 Tw T*
[(donors: are )-0.8 (they )-1.7 (due )-1.2 (to HTL)138.5 (V)73.3 (-I )-0.8 (or HTL)138.5 (V)73.3 (-II? )-1.3 (J )55.3 (Acquir )-0.6 (Immune )]TJ
0 Tw T*
[(Defic Syndr)132.1 (. 1992;5\(4\):400-4.)]TJ
0.467 Tw -1.772 -1.2 Td
(23.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Dood R)63.9 (Y)160.8 (. Hepa)-1.2 (titis )-1.5 (C virus, antib)-1.5 (odies, )-0.7 (and )-1.2 (infectivity: )]TJ
0.02 Tw T*
[(parodox, pragmatism, )-2 (and )-1.6 (policy)122 (. )54.3 (Am )-0.7 (J Clin )-1.3 (P)47.2 (athol. )-1.6 (1992; )-2.5 (97: )]TJ
0 Tw T*
(4-6.)Tj
0.246 Tw -1.772 -1.2 Td
(24.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Bush )-1.2 (MP)195.2 (, )-0.7 (Klein)-0.6 (man )-1.4 (SH, )-1 (Jackson )-0.9 (B, )-0.8 (Stramer )-1.2 (SL, )-1.1 (Hewlett )-2.8 (I, )]TJ
0.177 Tw T*
[(P)47.3 (reston )-1 (S. )-0.8 (Nuclei )-1.9 (acid )-1.4 (amplification )-2.3 (testing )-2.3 (of blood donor )]TJ
0.048 Tw T*
[(for )1.1 (transfusion-tra)-1.1 (nsmitted )-1.9 (infectio)-0.9 (us diseases: )-1 (report of )0.8 (the )]TJ
0.257 Tw T*
[(interorganizational )-2.3 (task )-1.1 (force )0.5 (on nuclei )-1.4 (acid )-0.9 (amplification )]TJ
0 Tw T*
[(testing in blood donor)131.4 (. )17.6 (T)110.3 (ransfusion 2000;40\(2\):143-159. )]TJ
0.193 Tw 29.409 55.2 Td
(25.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Melve )-0.7 (GK, My)-0.7 (rmel )-0.7 (H, )-0.7 (Eide )-0.6 (GE, Hervig )17.9 (T)166.4 (. Evaluation )-1.4 (of )0.5 (the )]TJ
0.242 Tw T*
[(persistence )-1.8 (and )-1 (characteristics )-2.1 (of )0.7 (indeterminate )-3.7 (reactivity )]TJ
0.523 Tw T*
[(against )-2.1 (hepatitis )-2.9 (C )-0.6 (virus in )-1 (blood donors. )18.2 (T)110.3 (ransfusion. )]TJ
0 Tw T*
(2009;49\(11\):2359-65.)Tj
0.07 Tw -1.772 -1.2 Td
(26.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Schoofs )0.9 (M. )-0.7 (SIDA, la agon\355a )-0.9 (de \301frica. Merck )-1.1 (Sharp & Dohme. )]TJ
0 Tw T*
[(USA: )17.4 (The V)17 (illage V)63 (oice; 2000. )]TJ
-0.064 Tw -1.772 -1.2 Td
(27.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Busch )-1.1 (MP)195.3 (, )-0.6 (Lee )-1.5 (L, )-0.9 (Satten )-2.5 (GA, )-0.6 (Hen)-1.1 (rard DR, )-0.9 (Farzadegan )-1.6 (H, )-0.8 (Nelson )]TJ
0.22 Tw T*
[(KE, et )-0.7 (al. )17.6 (T)41.9 (ime )-0.8 (course of )0.5 (detection )-2.4 (of )0.5 (viral and )-1.1 (serologic )]TJ
0.334 Tw T*
[(markers preceding )-1.4 (human )-1.5 (immunodeficiency )-2.4 (virus type )-1.2 (1 )]TJ
-0.012 Tw T*
[(seroconversion: implications )-1.2 (for )1.1 (screening )-1.2 (of )0.7 (blood )0.6 (and )-0.9 (tissue )]TJ
0 Tw T*
[(donors. )18.4 (T)110.3 (ransfusion.1995; 35\(2\): 91-97.)]TJ
-0.044 Tw -1.772 -1.2 Td
(28.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Saville )-1.2 (RD, )-1.1 (Constantine )-3.2 (NT)166.3 (, )-0.9 (Cleghorn )-0.7 (FR, )-0.8 (Jack )-1.1 (N, )-1 (Bartholomew )]TJ
0.363 Tw T*
[(C, )-1 (Edwards )-0.6 (J, )-0.7 (et )-1.6 (al. )-1.1 (Fourth )-1.2 (Ge)-0.7 (neration )-2.1 (Enzyme-Linked )]TJ
0.432 Tw T*
[(Immunosorbent )53.7 (Assay for )0.9 (the )-1.4 (Simultaneous )-1.9 (detection )-2.4 (of )]TJ
0.101 Tw T*
[(Human )-2 (Immunodeficiency )-2.9 (V)17.6 (irus )54.8 (Antigen )-2.1 (and )53.9 (Antibody)121.1 (. )-0.6 (J Clin )]TJ
0 Tw T*
(Microbiol. 2001;39\(7\):2518-24.)Tj
-0.05 Tw -1.772 -1.2 Td
(29.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Y)55.3 (ilmaz G. Diag)-0.7 (nosis of )0.8 (HIV )-1 (infec)-0.7 (tion and )-0.8 (laboratory monitoring )]TJ
0 Tw T*
[(of its therapy)120.2 (. J Clin V)16.5 (irol. 2001 ; 21\(3\): 187-96.)]TJ
-0.119 Tw -1.772 -1.2 Td
(30.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Clinical )-1.5 (and )-1.3 (Laboratory )-0.9 (Standard)-1.5 (s Institute )-3.3 (\(CLSI\). )-1.7 (Interference )]TJ
0.2 Tw T*
[(T)124.9 (esting )-1.8 (in)-0.6 ( )-0.7 (Clinica)-1.2 (l )-0.6 (Chemistry; )53 (Approved )-0.6 (Guideline )-2.9 (- )-0.9 (Second )]TJ
0 Tw T*
[(Edition. CLSI document EP7-A2. W)51.1 (ayne, P)109.9 (A: CLSI; 2005.)]TJ
-0.078 Tw -1.772 -1.2 Td
(31.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Beelaert )-2.4 (G, )-1.2 (Fr)0.5 (ansen )-2.1 (K. )-0.6 (Evaluatio)-0.7 (n )-1.1 (of a )-1.1 (rapid )-1.2 (and )-1.6 (simple )-1.2 (fourth-)]TJ
0.175 Tw T*
[(generation )-2.2 (HIV )-1.3 (screening )-1.6 (assay )-0.9 (for)1.1 ( qualitative )-2.9 (detection )-2.5 (of )]TJ
0.028 Tw T*
[(HIV )-1 (p24 )-1 (antigen )-2.2 (and/or )-0.6 (antibodies )-1.7 (to HIV)72.7 (-1 )-0.6 (and )-0.9 (HIV)72.7 (-2. )-0.8 (J V)17.7 (irol )]TJ
0 Tw T*
(Methods. 2010; 168\(1\):218-22.)Tj
0.009 Tw -1.772 -1.2 Td
(32.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(S\341nchez )54.2 (AS, Gonzales NP)195.5 (, )55.3 (Alvarez )0.6 (VJ. Costos )0.9 (en )-0.6 (la )18 (T)110.3 (ransfusi\363n )]TJ
0 Tw T*
[(Sangu\355nea. R)37.6 (ev Mex )53.6 (Anest. 2000;23\(2\): 66-70.)]TJ
/CS0 cs 1 scn
/GS0 gs
/TT1 1 Tf
-1.772 -2.45 Td
(Fuentes de financiamiento:)Tj
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
T*
(Este art\355culo ha sido financiado por los autores.)Tj
/CS0 cs 1 scn
/GS0 gs
/TT1 1 Tf
0 -2.45 TD
(Conflictos de inter\351s:)Tj
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 -1.2 TD
(Los autores declaran no tener ning\372n conflicto de inter\351s.)Tj
/CS0 cs 1 scn
/GS0 gs
/TT1 1 Tf
0 -2.45 TD
(Correspondencia:)Tj
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 -1.2 TD
(Jeel Moya Salazar)Tj
T*
[(Direcci\363n: Jr)132.7 (. P)46.8 (acifico 957. Lima 07. 51001 Lima, P)38.8 (er\372.)]TJ
T*
[(T)124.9 (el\351fono: +051 1986014954.)]TJ
T*
(Correo electr\363nico: jeelms@outlook.com; jeel.moya.s@pch.pe)Tj
ET
/CS0 cs 1 scn
/GS0 gs
330.236 234.992 170.079 36.851 re
f
BT
0 0 0 0 k
9 0 0 9 342.7087 255.6693 Tm
[(R)40.5 (ecibido: 11 de setiembre de 2016)]TJ
0 -1.222 TD
(Aprobado: 08 de febrero de 2017)Tj
0 0 0 1 k
/GS1 gs
-0.734 53.652 Td
[(Jeel Moya-Salazar)140.8 (, Liz P)46.4 (io-D\341vila, R)39.2 (ommel D\355az R )]TJ
ET
endstream
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0.04 Tc 0 Tw 0 Ts 100 Tz 0 Tr 9 0 0 9 430.6147 32.9076 Tm
(enero - marzo 2017)Tj
ET
endstream
endobj
36 0 obj
<>
endobj
37 0 obj
<>
endobj
38 0 obj
<>stream
H\n0EY&< ($>T Z*2fwDTKgp-mZ@Iu`0V{+ލiڨmo5NHwpl0A9v'=p/荽Avs?8
@]Ɓ^zڏrZMui:>WmQ
}o(V
ՕV-4gmP߽U>
sCy91gK撸"Gcd,gqaD2ӐUɞe,O̧mǔ7(mxf)J\b"T +
endstream
endobj
39 0 obj
<>stream
HU TsDQ@{@HHQȜGpdT
Z&jAY|jhΚi"BPC{Q_Vk{9{9 <֦W4KpbrVcE F .''r Ӆ4kz_ 3\i9\r*h hY}<}M3rr/.@̱I=*u
ݚks"od'eI-ue
Ǹu|be&S1ATo+3jz
J4QH7lgsɉ
tNM$Qz>w4ݥkm7:uyoӰ{
hb-M5oѲUHhڴ]:<;uҵ[Tt#vG^A6|DBbF&g=&3+{u 9'MΝ2igϜ5{NsW8^g{ʋK.{WW\^5o}{;%ᄋ6lpGc?l݆O?|{َ_ڽg8x_9c+NTVAO%\3jڡf
MOM{4- \P: i6FG#dDVc1Xmn56ub66(o Z-AAotvF#U#e`YhZQz>O_`2K;XrV届ׅs*U$TU/)_89I6fCWRG"uFU~T<&֫5#b栀gb>^ƛX(+fY\E,'axg<yy/2HU_xy!&mߠ^60M\Aʤ4+U(A)-T62lܔ;IoqR[b8c)V*RuasTᘼ"Q8NHvaWvb4cc(1`Oboa_c@+8srs$d2S43/pGs1YXZ999I\NT>iNMϙٜ~qwn^~AKT`>U36Uak{{ fhfTڋ9yH[%8O-ت)@?ao-LOu?A^MSJuL5IMJ[/_
m[_&Y 5ƩH"-/ÁU8K>a(_ɛm
A6O%`v7uu#[f8ҎHeˌHAE<|q`}նm_+]